Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Combination therapy in clinical trials for treatment of Glioblastoma multiforme

From: Combination therapy to checkmate Glioblastoma: clinical challenges and advances

Target Molecule GBM type Stage of testing References
Alkylation mediated DNA damage Temozolomide (TMZ) + radiotherapy (RT) GBM Phase IV NCT00686725
αvβ3 and αvβ5 integrin inhibitor+ Cilengitide + TMZ + RT Newly diagnosed GBM patients with methylated MGMT promoter Phase III NCT00689221
Tyrosine kinase inhibitor Imatinib mesylate + hydroxyurea TMZ resistant progressive GBM Phase III NCT00154375
Pan-VEGFR tyrosine kinase inhibitor Cediranib + lomustine chemotherapy Recurrent GBM Phase III NCT00777153
VEGF-A Bevacizumab (Avastin®) + TMZ + RT Newly diagnosed GBM Phase III NCT00943826
Immunostimulant TMZ + RT + poly ICLC Newly diagnosed GBM Phase II NCT00262730
Multiple kinase inhibitor TMZ + RT + sorafenib GBM Phase II NCT00544817
Tubulin inhibitor TMZ + PPX (CT2103) GBM without MGMT methylation Phase II NCT01402063
mTOR inhibitor TMZ + RT + bevacizumab + everolimus GBM Phase II NCT00805961
VEGF-A + topoisomerase I inhibitor TMZ + avastin + irinotecan Unresectable/Multifocal GBM Phase II NCT00979017
EGFR inhibitor TMZ + bevacizumab + tarceva GBM Phase II NCT005255525